Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Simple item page
dc.contributor.authorAmuge, Pauline
dc.contributor.authorLugemwa, Abbas
dc.contributor.authorMujuru, Hilda A.
dc.contributor.authorKityo, Cissy M.
dc.contributor.authorAtwine, Lorna
dc.contributor.authorFord, Deborah
dc.date.accessioned2025-02-19T10:08:18Z
dc.date.available2025-02-19T10:08:18Z
dc.date.issued2022-09-17
dc.description.abstractYoung children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg.
dc.identifier.citationAmuge, P., Lugemwa, A., Wynne, B., Mujuru, H. A., Violari, A., Kityo, C. M., ... & Goodman, A. (2022). Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. The Lancet HIV, 9(9), e638-e648.
dc.identifier.otherf
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9970
dc.language.isoen
dc.publisherThe Lancet HIV
dc.titleOnce-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS2352301822001631.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences